Data from new clinical trials reported positive results of radioligand therapy over everolimus and sunitinib, and explore the combination of everolimus and somatostatin analogues

Study confirms favourable safety profiles and encouraging efficacy of an anti-claudin 18.2 antibody-drug conjugate

The latest tumour types covered in the ESMO PAGAs are biliary tract cancers, oncogene-addicted metastatic non-small cell lung cancer and epithelial ovarian cancer

Promising new data are presented for nivolumab plus ipilimumab and the single tremelimumab regular interval durvalumab regimen in Asian patients and those with impaired liver function

Early results from a phase III trial support 30-minutes infusions of immunotherapy with some advantages for patients

Strategies to target MTAP deletion, KRAS G12D and ESR1 mutations, and CDK4 and CDK2 further expand the landscape of precision oncology

However, the future of TKI combinations for these rare tumours is uncertain

Preliminary results from three clinical trials reveal some benefits of cetuximab plus irinotecan, amivantamab plus FOLFOX or FOLFIRI and ramucirumab plus standard of care for patients with mCRC, including after progression on standard therapies 

Three-year disease-free survival data from NICHE-2 and findings from NICHE-3 add to current knowledge on the benefits of immune checkpoint inhibition in this setting 

Positive data presented from the LEAP-012 study for intermediate-stage disease, but it is still unclear how these will influence clinical practice